Supporting Information for
Metabolome-wide association study on ABCA7 indicates a role for ceramide metabolism in Alzheimer’s disease

Abbas Dehghan1-3*, Rui Climaco Pinto1, 3, Ibrahim Karaman1, 3, Jian Huang1, 3, 4, Brenan R Durainayagam1, 3, 5, Mohsen Ghanbari6, Areesha Nazeer6, Qi Zhong3, 5, Sonia Liggi5, Luke Whiley7, 8, Rima Mustafa1, Miia Kivipelto9-11, Alina Solomon10-12, Tiia Ngandu11, 13, Takahisa Kanekiyō14, Tomonori Aikawa14, Carola I. Radulescu3, Samuel J. Barnes3, Gonçalo Graça15, Elena Chekmeneva16, 17, Stephane Camuzeaux16, 17, Matthew R Lewis17, 18, Manuja R Kaluarachchi3, 5, M Arfan Ikram6, Elaine Holmes3, 5, 7-8, Ioanna Tzoulaki1, 3, 18, Paul M Matthews3, 19, 20, Julian L Griffin3, 5, 21, Paul Elliott1-3, 20, 22-23*

Affiliations:

1Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London; Norfolk Place, London, UK.
2MRC Centre for Environment and Health, School of Public Health, Imperial College London; Norfolk Place, London, UK.
3UK Dementia Research Institute at Imperial College London; Burlington Danes Building, Hammersmith Hospital, DuCane Road, London W12 0NN UK.
4Singapore Institute for Clinical Sciences (SICS), Agency for Science, Technology and Research (A*STAR); Singapore.
5Biomolecular Medicine, Division of Systems Medicine, Department of Metabolism, Digestion and Reproduction, Imperial College London; London, United Kingdom.
6Department of Epidemiology, Erasmus University Medical Center; Rotterdam, the Netherlands.7Australian National Phenome Centre, Computational and Systems Medicine, Health Futures Institute, Murdoch University; Harry Perkins Building, Perth, Western Australia 6150, Australia.
8Perron Institute for Neurological and Translational Science; Nedlands, Western Australia 6009, Australia.
Corresponding author

Professor Paul Elliott, MRC Centre for Environment and Health, Department of Epidemiology and Biostatistics, School of Public Health, Imperial College of Science Technology and Medicine, London W2 1PG, United Kingdom

Email: p.elliott@imperial.ac.uk
Abbas Dehghan MD PhD, Department of Epidemiology & Biostatistics, School of Public Health, Imperial College of Science Technology and Medicine, London W2 1PG, United Kingdom
Email: a.dehghan@imperial.ac.uk

This PDF file includes:

- Supplementary methods
- Supplementary results
- Footnotes for Supplementary Table 2
- Figures S1 to S7
- SI References

Other supporting materials for this manuscript include the following:

- Datasets S1 to S19
Supplementary methods

*NAPE synthesis*

The protocol for the synthesis of NAPEs was adapted from Basit et al.\(^1\) For the synthesis of NAPE(P-18:0/20:4/16:0), NAPE(P-18:0/20:4/18:1), and NAPE(P-18:0/20:4/18:0), 1 mg (0.00133 mmol) of 1-(1Z-octadecenyl)-2-arachidonoyl-sn-glycero-3-phosphoethanolamine (PE(P-18:0/20:4), Avanti Polar Lipids) was aliquoted as 1 mL of 1 mg/mL supplied solution in chloroform to a precooled glass vial, and 0.55 mg of triethylamine were added in gently, stirring the mixture in the vial. An appropriate acyl chloride (16:0, 18:1 or 18:0, 0.0053 mmol each) in 0.1 mL chloroform was added dropwise to the mixture. After the addition of acyl chloride was complete, the reaction mixtures were heated to 40 °C for two hours and stirred overnight at room temperature. The reactions were quenched by adding 0.2 mL of a saturated sodium bicarbonate solution. The organic layers were collected and washed with 0.3 mL of 0.01 M hydrochloric acid and 0.3 mL of brine. The reaction mixtures were dehydrated with sodium sulfate. The solution was decanted in a clean vial and dried down under the stream of nitrogen. The product was resuspended in 0.1 mL of chloroform and purified using silica gel SPE cartridges (Phenomenex) using gradient elution with chloroform/methanol (1-20% methanol) mixture. The synthesis of NAPE(P-18:0/18:1/16:0) was carried out using the same protocol with 1-(1Z-octadecenyl)-2-oleoyl-sn-glycero-3-phosphoethanolamine (PE(P-18:0/18:1), Avanti Polar Lipids) and palmitoyl chloride as starting materials.

**Supplementary results**

As these were young mice, we also explored the effect of ageing in a transcriptomics dataset of brain tissue from the APP/PS1 mouse (GEO GSE 86828) to examine whether ageing may perturb sphingolipid metabolism in this model of early-onset AD. OPLS-DA readily separated 7 and 18-month-old animals according to the transcriptional profile of sphingolipid metabolism and ABCA transport genes. Ageing was associated with the increased translation of Abca9, Abca1
and CerS6. Overall, these data suggest that altered sphingolipid metabolism may be a shared mechanism associated with both LOAD and EOAD, albeit a late stage of EOAD. Sphingolipid metabolism was also altered by inflammation and hence, we asked whether activation of microglia may also induce changes in sphingolipid metabolism.
Supplementary Table 2 - MWAS on 10 ABCA7 SNPs using untargeted National Phenome Centre LC-MS platforms (LNEG, LPOS, HPOS) and Metabolon

The table is in the attached excel file.

Footnotes:

**Metabolite annotation**: The pairs of numbers in brackets separated by colon are the carbon chain size followed by the number of double bonds (total number of carbons and double bonds in case it is not possible to discriminate the side chains). A “/” separates the different carbon side chains in the positions (sn-1/sn-2). An “and/or” indicates that the position of the double bonds on the same carbon side chain cannot be determined (in the case of ether or vinyl-ether bond at the sn-1 position of phospholipids (for example, O- and P-species)), while a “|” shows that the two compounds of known chain composition are coeluting.

**LC-MS platform**: For the untargeted UPLC-MS platforms used P means plasma; H/L means HILIC/Lipid; POS/NEG means positive or negative ionisation modes. The Metabolon platforms are presented in the Metabolon metadata, thus in addition to POS/NEG they can also be defined as early/late.

**Significance threshold**: Each SNP has its own multiple adjustment P-value threshold at a metabolome-wide significance level obtained through a permutation approach, ranging from $5.38 \times 10^{-5}$ to $1.01 \times 10^{-4}$.

**Ion type**: Square brackets [ ] are used to show ion species detected with its charge (positive or negative) following the brackets. The notation inside the parenthesis (M+n), where n=1,2,3, is used to indicate the isotopic signals that are detected in high-resolution mass spectra along with the main ions of different types.

**Annotation confidence level**: This is assigned according to Sumner et al., 2007. MS1 level 1 corresponds to identified compound compared to the authentic chemical standard analyzed in the same experimental conditions; level 2 corresponds to a putative annotation based on the comparison of analytical data to public spectral databases; level 3 corresponds to annotated class of metabolites; level 4 is for unknown.

**Metabolite abbreviation**: Some annotations are ambiguous in relation to the absolute identity of the metabolite as it is not possible to distinguish between multiple possible alternatives presented using these methods. The symbols *# are used to emphasize that (*) ‘O-’ prefix (alkyl ether substituent) and ‘P-’ prefix (1Z-alkenyl ether (vinyl) substituent) and (#) the position of double bonds have not been determined. The abbreviations as used elsewhere in the document are as follows: PA*: phosphatidic acid PA(O-18:1/20:4) and/or PA(P-18:0/20:4); LacCer: lactosylceramide; SHexCer: Sulfatide hexosylceramide. The five distinct NAPE metabolites are: NAPE1*: NAPE(P-18:1/18:1/16:0) and/or NAPE(O-18:0/18:1/16:0); NAPE2*: NAPE(P-18:1/22:5/18:0) and/or NAPE(O-18:0/22:5/18:0) and NAPE(P-18:1/22:4/18:1) and/or NAPE(O-
NAPE3*: NAPE(P-18:1/20:4/16:0) and/or NAPE(O-18:0/20:4/16:0); NAPE4*: NAPE(P-18:1/20:4/18:0) and/or NAPE(O-18:0/20:4/18:0); NAPE5*: NAPE(P-18:1/20:4/18:1) and/or NAPE(O-18:0/20:4/18:1).

**NAPE annotations**: Although compared to the synthesized standards obtained using commercially available plasmenyl forms of starting phosphoethanolamines (PE(P-18:0/20:4) and PE(P-18:0/18:1)), these are assigned a level of confidence of 3 corresponding to metabolite class since it is impossible to distinguish plasmenyl and either form of glycerophospholipids by MS/MS.
Supplementary Figure 1. The average levels of LacCer(d18:1/24:1) measured by serum lipid negative LC-MS in the Airwave Study per copy alleles of rs3752246
Supplementary Figure 2. Association of change in metabolite levels with change in cognitive score in FINGER trial.
Supplementary Figure 3. Expression quantitative trait locus (eQTL) of $ABCA7$-related SNPs in whole blood, liver, and brain tissues (* False discovery rate<0.05; ** P<0.05/27).
Supplementary Figure 4. a. OPLS-DA scores plot (UV scaled) of 8-week-old Abca7+/− and control mice brain transcriptomic data involved in sphingolipid metabolism. R^2_X=91%, R^2_Y=98%, Q^2=47%, passed random permutation test. B. Loadings plot for scores plot shown in a. Green signifies variables of the model. Blue signifies class membership in the classification matrix. C. OPLS-DA scores plot (UV scaled) of App/PS1 and control mice brain transcriptomic data involved in sphingolipid metabolism. R^2_X=64%, R^2_Y=99%, Q^2=82% D. Loadings plot for scores plot shown in a. Green signifies variables of the model. Blue signifies class membership in the classification matrix. (Male mice, age: 54 to 59 days).
Supplementary Figure 5. OPLS-DA models to separate App^{NL-G-F} mouse brain samples from wild-type samples (10-month, female $n = 1$ and male $n = 10$). a) O-PLS-DA cross-validated scores plot (Pareto- scaled) of APP brain lipidomic data acquired in the positive mode. Each point represents one sample. R$^2_X$ 0.936, R$^2_Y$ 1, Q$^2$ 0.542, CV-ANOVA P-value 0.968. b) cross-validated permutation plot of the O-PLS-DA model built with APP brain lipidomic data acquired in the positive mode. c) O-PLS-DA cross-validated scores plot (Pareto scaled) of APP brain lipidomic data acquired in the negative mode. Each point represents one sample. R$^2_X$ 0.953, R$^2_Y$ 0.999, Q$^2$ 0.0165, CV-ANOVA P-value 1. d) cross-validated permutation plot of the O-PLS-DA model built with APP brain lipidomic data acquired in the negative ionization mode.
Supplementary Figure 6. High-resolution mass spectrometry fails to detect any changes in lactosyl- and hexosyl-ceramides in the mouse brain of the App<sup>NL-G-F</sup> mice (10-month, female n = 1 and male n = 10). Bar graphs of lactosyl- and hexosyl-ceramides detected in the brain of App<sup>NL-G-F</sup> mice. The mean ± standard deviation of the mean are shown. No significant difference for all lipids according to a Student’s t-test.
References

1. Basit, A., Pontis, S., Piomelli, D. & Armirotti, A. Ion mobility mass spectrometry enhances low-abundance species detection in untargeted lipidomics. *Metabolomics* **12**, 50 (2016).

2. Sumner, L.W., *et al.* Proposed minimum reporting standards for chemical analysis Chemical Analysis Working Group (CAWG) Metabolomics Standards Initiative (MSI). *Metabolomics* **3**, 211-221 (2007).